1. Ferenci P., Fried M., Labrecque D., Bruix J., Sherman M., Omata M., Heathcote J., Piratsivuth T., Kew M., Otegbayo J.A., Zheng S.S., Sarin S., Hamid S., Modawi S.B., Fleig W., et al. 2010. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): A global perspective. J. Gastrointestin. Liver Dis.
19 (3), 311–317.
2. Matsubara K., Tokino T. 1990. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol. Biol. Med. 7 (3), 243–260.
3. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. 2005. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell.
121 (7), 977‒990.
4. Moudi B., Heidari Z., Mahmoudzadeh-Sagheb H. 2019. Meta-analysis and systematic review of prognostic significance of Glypican-3 in patients with hepatitis B-related hepatocellular carcinoma. Virus Dis. 30 (2), 193‒200.
5. Moudi B., Heidari Z., Mahmoudzadeh-Sagheb H. 2018. Study of liver in HBV-related hepatocellular carcinoma: Stereology shows quantitative differences in liver structure. Eur. J. Histochem. 62 (3), 238‒246.